Citation: | Dong Yan, Zhao Hong, Man Jiangwei, et al. Expression and role of matrix metalloproteinase in injury related renal transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(6): 760-764. doi: 10.3969/j.issn.1674-7445.2020.06.018 |
[1] |
张洪海, 孙玉, 刘芳, 等.肝细胞癌患者血浆基质金属蛋白酶的检测及临床意义[J].临床肝胆病杂志, 2019, 35(4):825-829. DOI: 10.3969/j.issn.1001-5256.2019.04.023.
ZHANG HH, SUN Y, LIU F, et al. Determination and clinical significance of plasma matrix metalloproteinase in patients with hepatocellular carcinoma[J]. J Clin Hepatol, 2019, 35(4):825-829. DOI: 10.3969/j.issn.1001-5256.2019.04.023.
|
[2] |
CUI N, HU M, KHALIL RA. Biochemical and biological attributes of matrix metalloproteinases[J]. Prog Mol Biol Transl Sci, 2017, 147:1-73. DOI: 10.1016/bs.pmbts.2017.02.005.
|
[3] |
MARINO-PUERTAS L, GOULAS T, GOMIS-RÜTH FX. Matrix metalloproteinases outside vertebrates[J]. Biochim Biophys Acta Mol Cell Res, 2017, 1864(11 Pt A):2026-2035. DOI: 10.1016/j.bbamcr.2017.04.003.
|
[4] |
康玲玲, 高端敏.三七皂苷R1对心房颤动大鼠心肌炎症相关因子和金属基质蛋白酶表达的影响[J].中山大学学报(医学科学版), 2019, 40(6):921-929. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zsykdxxb201906016
KANG LL, GAO DM. Effects of notoginsenoside R1 on expression of myocardial inflammation-related factors and metalloproteinase in atrial fibrillation rats[J]. J Sun Yat-sen Univ (Med Sci), 2019, 40(6):921-929 http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zsykdxxb201906016
|
[5] |
BAŁKOWIEC M, MAKSYM RB, WŁODARSKI PK. The bimodal role of matrix metalloproteinases and their inhibitors in etiology and pathogenesis of endometriosis (review)[J]. Mol Med Rep, 2018, 18(3):3123-3136. DOI: 10.3892/mmr.2018.9303.
|
[6] |
MALEMUD CJ. Inhibition of MMPs and ADAM/ADAMTS[J]. Biochem Pharmacol, 2019, 165:33-40. DOI: 10.1016/j.bcp.2019.02.033.
|
[7] |
MONTANER J, RAMIRO L, SIMATS A, et al. Matrix metalloproteinases and ADAMs in stroke[J]. Cell Mol Life Sci, 2019, 76(16):3117-3140. DOI: 10.1007/s00018-019-03175-5.
|
[8] |
INKINEN KA, SOOTS AP, KROGERUS LA, et al. Fibrosis and matrix metalloproteinases in rat renal allografts[J]. Transpl Int, 2005, 18(5):506-512. DOI: 10.1111/j.1432-2277.2004.00053.x.
|
[9] |
TOMITA M, KOIKE H, HAN GD, et al. Decreased collagen-degrading activity could be a marker of prolonged mesangial matrix expansion[J]. Clin Exp Nephrol, 2004, 8(1):17-26. DOI: 10.1007/s10157-003-0258-7.
|
[10] |
OGBUREKE KU, FISHER LW. Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs)[J]. Kidney Int, 2005, 68(1):155-166. DOI: 10.1111/j.1523-1755.2005.00389.x.
|
[11] |
KIM SS, SHIN N, BAE SS, et al. Enhanced expression of two discrete isoforms of matrix metalloproteinase-2 in experimental and human diabetic nephropathy[J]. PLoS One, 2017, 12(2):e0171625. DOI: 10.1371/journal.pone.0171625.
|
[12] |
FANG X, SUN R, HU Y, et al. miRNA-182-5p, via HIF2α, contributes to arsenic carcinogenesis: evidence from human renal epithelial cells[J]. Metallomics, 2018, 10(11):1607-1617. DOI: 10.1039/c8mt00251g.
|
[13] |
CARON A, DESROSIERS RR, LANGLOIS S, et al. Ischemia-reperfusion injury stimulates gelatinase expression and activity in kidney glomeruli[J]. Can J Physiol Pharmacol, 2005, 83(3):287-300. DOI: 10.1139/y05-011.
|
[14] |
BERNAL F, HARTUNG HP, KIESEIER BC. Tissue mRNA expression in rat of newly described matrix metalloproteinases[J]. Biol Res, 2005, 38(2/3):267-271. DOI: 10.4067/s0716-97602005000200016.
|
[15] |
NARULA S, TANDON C, TANDON S. Role of matrix metalloproteinases in degenerative kidney disorders[J]. Curr Med Chem, 2018, 25(15):1805-1816. DOI: 10.2174/0929867325666171205143441.
|
[16] |
BONVENTRE JV. Mechanisms of ischemic acute renal failure[J]. Kidney Int, 1993, 43(5):1160-1178. DOI: 10.1038/ki.1993.163.
|
[17] |
CARON A, DESROSIERS RR, BÉLIVEAU R. Ischemia injury alters endothelial cell properties of kidney cortex: stimulation of MMP-9[J]. Exp Cell Res, 2005, 310(1):105-116. DOI: 10.1016/j.yexcr.2005.07.004.
|
[18] |
KUNUGI S, SHIMIZU A, KUWAHARA N, et al. Inhibition of matrix metalloproteinases reduces ischemia-reperfusion acute kidney injury[J]. Lab Invest, 2011, 91(2):170-180. DOI: 10.1038/labinvest.2010.174.
|
[19] |
COVINGTON MD, BURGHARDT RC, PARRISH AR. Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14)[J]. Am J Physiol Renal Physiol, 2006, 290(1):F43-F51. DOI: 10.1152/ajprenal.00179.2005.
|
[20] |
FU H, ZHOU D, ZHU H, et al. Matrix metalloproteinase-7 protects against acute kidney injury by priming renal tubules for survival and regeneration[J]. Kidney Int, 2019, 95(5):1167-1180. DOI: 10.1016/j.kint.2018.11.043.
|
[21] |
MOSER MA, ARCAND S, LIN HB, et al. Protection of the transplant kidney from preservation injury by inhibition of matrix metalloproteinases[J]. PLoS One, 2016, 11(6):e0157508. DOI: 10.1371/journal.pone.0157508.
|
[22] |
LAPLANTE A, LIU D, DEMEULE M, et al. Modulation of matrix gelatinases and metalloproteinase-activating process in acute kidney rejection[J]. Transpl Int, 2003, 16(4):262-269. DOI: 10.1007/s00147-002-0540-8.
|
[23] |
RODRIGO E, LÓPEZ-HOYOS M, ESCALLADA R, et al. Circulating levels of matrix metalloproteinases MMP-3and MMP-2 in renal transplant recipients with chronic transplant nephropathy[J]. Nephrol Dial Transplant, 2000, 15(12):2041-2045. DOI: 10.1093/ndt/15.12.2041.
|
[24] |
TURUNEN AJ, LINDGREN L, SALMELA KT, et al. Matrix metalloproteinase-9 and graft preservation injury in clinical renal transplantation[J]. Transplant Proc, 2015, 47(10):2831-2835. DOI:10.1016/j.transproceed. 2015.10.056.
|
[25] |
MANKHEY RW, WELLS CC, BHATTI F, et al. 17beta-estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney[J]. Am J Physiol Regul Integr CompPhysiol, 2007, 292(2):R769-R777. DOI:10.1152/ajpregu. 00375.2006.
|
[26] |
PALOMAR R, MAYORGA M, RUIZ JC, et al. Markers of fibrosis in early biopsies of renal transplants[J]. Transplant Proc, 2005, 37(3):1468-1470. DOI: 10.1016/j.transproceed.2005.02.051.
|
[27] |
RACCA MA, NOVOA PA, RODRÍGUEZ I, et al. Renal dysfunction and intragraft proMMP9 activity in renal transplant recipients with interstitial fibrosis and tubular atrophy[J]. Transpl Int, 2015, 28(1):71-78. DOI: 10.1111/tri.12445.
|
[28] |
MAZANOWSKA O, ZABIŃSKA M, KOŚCIELSKA-KASPRZAK K, et al. Increased plasma matrix metalloproteinase-2 (MMP-2), tissue inhibitor of proteinase-1 (TIMP-1), TIMP-2, and urine MMP-2 concentrations correlate with proteinuria in renal transplant recipients[J]. Transplant Proc, 2014, 46(8):2636-2639. DOI: 10.1016/j.transproceed.2014.08.034.
|
[29] |
HIRT-MINKOWSKI P, MARTI HP, HÖNGER G, et al. Correlation of serum and urinary matrix metalloproteases/tissue inhibitors of metalloproteases with subclinical allograft fibrosis in renal transplantation[J]. Transpl Immunol, 2014, 30(1):1-6. DOI:10.1016/j.trim.2013. 11.004.
|
[30] |
KWIATKOWSKA E, DOMANSKI L, BOBER J, et al. Urinary metalloproteinases-9 and -2 and their inhibitors TIMP-1 and TIMP-2 are markers of early and long-term graft function after renal transplantation[J]. Kidney Blood Press Res, 2016, 41(3):288-297. DOI: 10.1159/000443431.
|
[31] |
SCOZZI D, IBRAHIM M, MENNA C, et al. The role of neutrophils in transplanted organs[J]. Am J Transplant, 2017, 17(2):328-335. DOI: 10.1111/ajt.13940.
|
[32] |
UCHIDA Y, FREITAS MC, ZHAO D, et al. The protective function of neutrophil elastase inhibitor in liver ischemia/reperfusion injury[J]. Transplantation, 2010, 89(9):1050-1056. DOI: 10.1097/TP.0b013e3181d45a98
|
[33] |
YAO W, HAN X, GUAN Y, et al. Neutrophil elastase inhibitors suppress oxidative stress in lung during liver transplantation[J]. Oxid Med Cell Longev, 2019:7323986. DOI: 10.1155/2019/7323986.
|
[34] |
JU YN, GENG YJ, WANG XT, et al. Endothelial progenitor cells attenuate ventilator-induced lung injury with large-volume ventilation[J]. Cell Transplant, 2019, 28(12):1674-1685. DOI: 10.1177/0963689719874048.
|